What is perflutren?
Perflutren is an ultrasound contrast agent that is used to improve the quality of an echocardiogram (ultrasound of the heart). Perflutren works by changing the way ultrasound waves travel within your heart. This helps the ultrasound portray a sharper image of your heart.
Perflutren is used to allow certain segments of the heart to be seen more clearly on an echocardiogram.
Perflutren may also be used for purposes not listed in this medication guide.
You should not be treated with perflutren if you have a genetic heart condition called "cardiac shunt."
In rare cases, serious or fatal reactions may occur during the injection or shortly afterward. Tell your caregiver right away if you feel dizzy, nauseated, light-headed or short of breath, or if you have a severe headache, pounding in your ears, chest pain, fast or slow heartbeats, wheezing, or shallow breathing.
Before taking this medicine
You should not be treated with perflutren if you are allergic to it, or if you have:
a genetic heart condition called "cardiac shunt"; or
if you are allergic to blood products or to a medicine that contains albumin.
To make sure perflutren is safe for you, tell your doctor if you have:
a congenital heart defect;
a lung condition that has recently become worse; or
if you have ever had an allergic reaction during a blood transfusion.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether perflutren passes into breast milk or if it could harm a nursing baby. However, if you are breast-feeding a baby, use a breast pump to empty your milk supply one time after you are treated with perflutren. Throw out the milk you collect during this time and do not feed it to your baby.
Perflutren is made from human plasma (part of the blood) which may contain viruses and other infectious agents. Donated plasma is tested and treated to reduce the risk of it containing infectious agents, but there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.
How is perflutren given?
Perflutren is injected into a vein through an IV. A healthcare provider will give you this injection just before the start of your echocardiogram.
Your heart rate, breathing, blood pressure, oxygen levels, and other vital signs will be watched closely for at least 30 minutes after you receive perflutren. This is to make sure you do not have an allergic reaction to the medicine.
What happens if I miss a dose?
Since perflutren is given with an echocardiogram, you will not be on a regular dosing schedule.
What happens if I overdose?
Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid after receiving perflutren?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Perflutren side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives, skin redness, itching; warmth, redness, numbness, or tingly feeling; wheezing, trouble breathing, tight feeling in your chest or throat; swelling of your face, lips, tongue, or throat.
In rare cases, serious or fatal reactions may occur during the injection or shortly afterward. Tell your caregivers right away if you have:
a light-headed feeling, like you might pass out;
severe dizziness, or a cold sweat;
chest pain, wheezing, trouble breathing;
fast or slow heartbeats;
severe headache, blurred vision, pounding in your neck or ears, anxiety, confusion; or
You may be more likely to have a serious reaction if you have severe or uncontrolled heart problems (congestive heart failure, a recent heart attack, serious heart rhythm disorder).
Common side effects may include:
flushing (warmth, redness, or tingly feeling);
pain in your side or lower back; or
pain, swelling, or irritation where the injection was given.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
Perflutren dosing information
Usual Adult Dose for Echocardiography:
-Administer by IV bolus or IV infusion immediately after activation in the VIALMIX(R) apparatus; if more than 5 minutes elapses before use, resuspend with 10 seconds of hand agitation
-Administer 10 microL/kg IV bolus; follow with a 10 mL saline flush
-If necessary, a second 10 microL/kg IV bolus (followed with a 10 mL saline flush) may be administered 30 minutes later to prolong contrast enhancement
Maximum dose: 2 bolus doses
-Prepare an IV infusion by adding 1.3 mL activated Definity(R) suspension to 50 mL of preservative-free saline
-Begin IV infusion at 4 mL/minute; may titrate up to 10 mL/minute to achieve optimal image enhancement
Maximum Infusion Rate: 10 mL/minute
Maximum Dose: One IV infusion
Comments: The safety of bolus and infusion dosing in combination or in sequence has not been studied.
-Dose should be individualized taking into account body habitus, intervening lung tissue, adequacy of transducer skin interface, and other acoustic factors.
-Time from resuspension to injection should not exceed 1 minute, if time is exceeded, resuspend the microspheres.
-Initial dose: 0.5 mL IV into peripheral vein at a rate not to exceed 1 mL per second; follow with a flush of NS or D5W
-Additional doses in increments of 0.5 mL up to a cumulative dose of 5 mL in a 10 minute period may be administered if contrast enhancement is inadequate
-Maximum dose per study: 8.7 mL
Use: As an ultrasound contrast agent to opacify the left ventricular chamber and improve the delineation of the left ventricular endocardial borders in patients with suboptimal echocardiograms.
What other drugs will affect perflutren?
Other drugs may interact with perflutren, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
More about perflutren
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 1 Review – Add your own review/rating
- Drug class: ultrasound contrast media
- Perflutren Lipid Microspheres
- Perflutren Protein Type A
- Perflutren lipid microsphere Intravenous (Advanced Reading)
- Perflutren protein type a microsphere Intravenous (Advanced Reading)
Related treatment guides
Where can I get more information?
- Your doctor or pharmacist can provide more information about perflutren.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 3.02.
Date modified: January 03, 2018
Last reviewed: September 06, 2017